SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated March 21, 2022, discloses a material definitive agreement entered into by BioSig Technologies, Inc. The company, incorporated in Delaware and headquartered in Westport, Connecticut, operates in the medical technology sector, specifically focusing on the PURE EP System. The report details a registered direct offering that closed on March 22, 2022.
Key Financial Metrics
The filing does not provide standard periodic financial metrics such as revenue, profit, cash flow, margins, or existing debt levels. The primary financial data relates to the capital raise:
- Gross Proceeds: Approximately $3.0 million.
- Net Proceeds: Approximately $3.0 million (after deducting fees and expenses).
- Shares Issued: 2,613,130 shares of Common Stock at $1.15 per share.
- Warrants Issued: Warrants to purchase up to 2,613,130 shares at an exercise price of $1.40 per share.
- Warrant Terms: Exercisable six months after issuance; expire three and one-half years after issuance.
Material Changes
The material change reported is the expansion of the company's capital base through the issuance of new equity and warrants. This transaction increases the total number of outstanding shares and warrants, potentially diluting existing shareholders. The filing does not provide comparative financial data against prior periods as it is a current event report rather than a periodic financial statement.
Guidance, Outlook, and Use of Proceeds
Management intends to use the net proceeds from the offering for the following purposes:
- Continuation of commercialization activities related to the PURE EP System.
- Additional support for organizational development.
- Funding working capital.
- General corporate purposes.
The filing includes standard risk disclosures regarding the Purchase Agreement, noting that representations and warranties are for the benefit of the parties to the agreement and may not reflect materiality standards viewed by stockholders. No specific forward-looking guidance on revenue or earnings was provided in this document.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-offering to assess dilution impact.
- Confirm the current cash balance and burn rate to evaluate the runway provided by the $3.0 million net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for any restrictive covenants or registration rights.
- Monitor the status of the PURE EP System commercialization to validate the stated use of proceeds.
- Check subsequent filings for any changes in the company's liquidity position or additional financing needs.